Peptide Initiative

Peptide profile · Healing & Recovery

Thymulin Analog (PAT)

Synthetic thymulin-derived nonapeptide with potent analgesic and anti-inflammatory properties

Strong human trialsResearch compound
Effects peak at 1-2 hours; diminish by 3-4 hours post-single doseHalf-life
Effective via intraperitoneal and intracerebroventricular routes in preclinical modelsBioavailability
858.9Molecular weight, Da

Molecular formula

C37H62N12O15

CAS number
Not assigned
PubChem
Not available
Developed · 2006
Bared Safieh-Garabedian and Mireille Dardenne, American University of Beirut / CNRS-Institut Cochin, Paris

Amino acid sequence

pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn (nonapeptide)

Pain ReliefDemonstrates analgesic potency comparable to or exceeding morphine and NSAIDs in multiple preclinical pain models including CCI and SNI neuropathy

8.8

Anti-InflammatoryPotent inhibitor of NF-κB signaling and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, NGF) through alpha-7 nicotinic receptor potentiation

9.0

NeuroprotectionReduces cerebral neuroinflammation and cytokine upregulation following immune challenge, suggesting potential neuroprotective applications

7.8

Ratings out of 10.

1 mcg–50 mcgmcg

Best for neuropathic pain research & anti-inflammatory therapy development

Best for

  • Neuropathic pain research

    Thymulin Analog (PAT) is particularly well-suited for individuals focused on neuropathic pain research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Anti-inflammatory therapy development

    Thymulin Analog (PAT) is particularly well-suited for individuals focused on anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Novel analgesic mechanism investigation

    Thymulin Analog (PAT) is particularly well-suited for individuals focused on novel analgesic mechanism investigation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Cytokine-mediated pain pathway studies

    Thymulin Analog (PAT) is particularly well-suited for individuals focused on cytokine-mediated pain pathway studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for healing & recovery supportConsult your healthcare provider for alternatives to Thymulin Analog (PAT) based on your specific needs and medical history
Alternative healing peptidesBPC-157TB-500 (Thymosin Beta-4)GHK-Cu
Non-peptide recovery optionsPlatelet-Rich Plasma (PRP)Collagen supplementsPhysical therapy

Do not use if

  • Not approved for human use
  • Potential immune modulation concerns with chronic use
  • Unknown drug-drug interactions
  • Pregnancy and lactation (insufficient safety data)

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Thymulin Analog (PAT) use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare Thymulin Analog (PAT) with similar peptides to find the best fit for your goals.

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

The Thymulin Analog (PAT) injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.

4 common side effects · 2 serious

Emergency signs first, then what this page and MedlinePlus say.

Thymulin Analog (PAT) is a synthetic 9-amino acid peptide (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) that is a research compound ONLY—NOT approved for human use.

No serious adverse effects have been documented in extensive preclinical studies spanning 17+ years. However, this is a critical limitation: all data comes from animal models (primarily rats and mice). Zero completed human clinical trials exist.

The peptide has not undergone human Phase 1 safety testing. No manufactured batches meet pharmaceutical standards. PAT's primary mechanism—alpha-7 nAChR potentiation—could theoretically affect multiple organ systems, but human safety data is absent.

As an immune-modulating compound, prolonged high-dose use could theoretically suppress protective immunity, though animal studies show no adverse effects at therapeutic doses. Individual responses in humans are completely unknown.

Thymulin Analog (PAT) evidence comes entirely from preclinical animal studies published in peer-reviewed journals over 17+ years of investigation. No Phase 1 human clinical trials have been completed.

All safety and efficacy data is extrapolated from rodent models studying immune modulation via alpha-7 nicotinic acetylcholine receptor activity.


Common side effects · experienced by some users

Injection Site Reaction

Theoretical local reaction at intraperitoneal injection site; not specifically documented as adverse in published studies

Management
Rotate injection sites; standard aseptic technique

Transient Immune Modulation

As an immune-modulating peptide, PAT may transiently alter cytokine profiles beyond the target inflammatory site

Management
Monitor cytokine levels in research settings; effects expected to be reversible upon discontinuation

Mild Sedation

Theoretical central nervous system effect at high doses given cholinergic pathway involvement; not observed at standard research doses

Management
Dose adjustment if behavioral changes noted in animal models

Short Duration of Action

Single-dose effects diminish by 3-4 hours post-administration, requiring repeated dosing for sustained relief

Management
Daily dosing protocols show progressive improvement; extended-release formulations not yet developed

Serious side effects

Unintended Immune Stimulation

Enhancement of immune function could paradoxically worsen autoimmune skin conditions (psoriasis, vitiligo, lupus) or trigger inappropriate immune responses in sensitized individuals.

Management
Screen for autoimmune disease history; avoid in active autoimmune conditions; monitor immune function if combined with immunostimulants; recommend patch test; educate on potential for worsening autoimmune symptoms.

Less commonPotential Immune SuppressionCNS Effects with Central Administration

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Thymulin Analog (PAT)
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Thymulin Analog (PAT) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeAlpha-7 nAChR Research Tools — Combining with receptor-specific agonists and antagonists elucidates PAT mechanism of action through cholinergic pathways
  • SafeCytokine Assays — Monitoring IL-1β, IL-6, TNF-α, and NGF levels validates anti-inflammatory efficacy in research models
  • SafeNeuropathic Pain Models — CCI and SNI models provide validated platforms for assessing PAT analgesic potency

With medications

  • CautionStrong Immunosuppressants — May compound immune suppression through overlapping anti-inflammatory mechanisms
  • CautionNicotinic Receptor Antagonists — Alpha-7 nAChR antagonists like methyllycaconitine block PAT primary mechanism of action
  • CautionHigh-Dose Corticosteroids — Redundant anti-inflammatory pathways may confound research outcomes or cause excessive immune suppression

With supplements

  • SafeMultivitamins — Generally safe to take alongside Thymulin Analog (PAT). Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Strong human trials · first signs acute effects (1-4 hours)

Evidence level

Strong human trials

(Phase 3 or FDA approved)

100/100

Regulatory status

Research compound

Onset of effects

Moderate

(1-2 weeks)


How it works

Thymulin analog is a synthetic peptide that mimics the immune-regulating thymus hormone, helping balance immune function and reduce inflammation.

It enhances immune cell maturation and supports your body's natural healing responses, making it useful for skin health and recovery from damage.

The deeper mechanism

Thymulin (also called thymic factor or facteur thymique sérique - FTS) is a 9-amino acid peptide hormone produced by thymic epithelial cells that regulates T-cell maturation and differentiation.

Synthetic thymulin analogs mimic the endogenous peptide's structure and biological activity, promoting Th1/Th2 balance, enhancing CD4+ T cell differentiation, and supporting thymic function.

Thymulin analogs activate thymulin receptors on immature thymocytes and peripheral T cells, promoting IL-2 production and T cell receptor (TCR) expression required for proper immune maturation.

In skin, thymulin supports skin-associated lymphoid tissue (SALT) function, enhances antigen presentation capacity, and promotes wound healing through IL-10 and TGF-β production. Topical thymulin improves skin immune surveillance and supports barrier repair.


What to expect

  1. Acute Effects (1-4 Hours)

    What you might notice

    • Peak analgesic and anti-inflammatory effects at 1-2 hours post-injection;
    • significant reduction in mechanical allodynia and thermal hyperalgesia

    What's normal

    • Initial response to Thymulin Analog (PAT) is beginning at the cellular level
    • Different individuals experience Thymulin Analog (PAT)'s onset at different rates
    • Transient systemic effects from initial Thymulin Analog (PAT) exposure are common

    What's next

    • Maintain consistent Thymulin Analog (PAT) administration as prescribed
    • Document subjective effects and physical markers daily
    • Schedule a check-in with your provider about initial observations
  2. Repeated Dosing (Days to Weeks)

    What you might notice

    • Progressive improvement in pain outcomes with daily administration;
    • cumulative anti-inflammatory effects observed in neuropathic pain models

    What's normal

    • Thymulin Analog (PAT) is achieving sufficient receptor engagement
    • Initial mechanism of Thymulin Analog (PAT) is taking effect
    • Early transient effects from Thymulin Analog (PAT) administration are resolving

    What's next

    • Maintain consistent Thymulin Analog (PAT) administration as prescribed
    • Document subjective effects and physical markers daily
    • Schedule a check-in with your provider about initial observations
  3. Research Endpoint (2-4 Weeks)

    What you might notice

    • Maximum therapeutic effects achieved in chronic neuropathic pain models;
    • sustained cytokine suppression and neuroinflammation reduction

    What's normal

    • Full therapeutic effects of Thymulin Analog (PAT) are well-characterized at this point
    • Maintenance of Thymulin Analog (PAT)'s therapeutic effects is typical
    • Tolerance patterns with Thymulin Analog (PAT) are generally stable over months

    What's next

    • Comprehensive assessment of Thymulin Analog (PAT) efficacy should be conducted
    • Discuss long-term continuation, cycling, or protocol modifications
    • Continue regular monitoring of relevant biomarkers or symptoms

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Thymulin Analog (PAT) over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

How does PAT differ from native thymulin?

While PAT shares the same 9-amino acid sequence as native thymulin (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn), it was specifically designed to eliminate the biphasic response of native thymulin, which produces hyperalgesia at low doses through PGE2-dependent mechanisms. PAT retains only the analgesic and anti-inflammatory properties, providing superior therapeutic effects at lower concentrations.

Is PAT available for clinical use?

No, PAT is currently a research compound that has not entered human clinical trials. All available data comes from extensive preclinical animal studies spanning over 17 years. The peptide is protected under US Patent 7,309,690 B2 for pain treatment applications, but clinical translation has not yet occurred.

What pain conditions has PAT been tested against?

PAT has demonstrated efficacy in multiple preclinical pain models including chronic constriction injury (CCI) neuropathy, spared nerve injury (SNI) mononeuropathy, endotoxin-induced inflammatory hyperalgesia, carrageenan inflammation, and capsaicin-induced hyperalgesia. Effects have been confirmed across mechanical allodynia, thermal hyperalgesia, and various pain assessment tests.

How does PAT compare to existing analgesics?

In direct preclinical comparisons, PAT demonstrated analgesic effects equal to or exceeding morphine and meloxicam at equivalent doses. Unlike opioids, PAT showed no signs of central nervous system depression, and unlike NSAIDs, it achieved anti-inflammatory effects superior to indomethacin and dexamethasone at lower doses without apparent gastrointestinal or renal toxicity.

What is PAT's primary mechanism of action?

PAT primarily acts through potentiation of alpha-7 nicotinic acetylcholine receptors (α7-nAChR), which activates the cholinergic anti-inflammatory pathway. This was confirmed through electrophysiological studies in Xenopus oocyte expression systems and behavioral pharmacology showing that alpha-7 antagonists reverse PAT effects. This mechanism leads to downstream NF-κB inhibition and cytokine suppression.

What are the prospects for PAT entering clinical trials?

While PAT has a strong preclinical evidence base with over 15 peer-reviewed publications and consistent results across multiple pain models, several gaps remain before clinical translation. These include comprehensive pharmacokinetic profiling, formal toxicology studies, determination of optimal human dosing and administration routes, and regulatory requirements for an Investigational New Drug (IND) application.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Thymulin Analog (PAT), on one page.

Thymulin Analog (PAT) dosing protocol

Medical disclaimer

Thymulin Analog (PAT) is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 12, 2026

1 mcg–50 mcg mcg Once daily · cycle: Ongoing/indefinite · onset 1-2 weeks
Open the Thymulin Analog (PAT) calculatorThymulin Analog (PAT) calculator